Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.

Saved in:
Bibliographic Details
Title: Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.
Authors: Loper M; College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA matthewloper18@gmail.com., Qadar A; The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Vesely SK; The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Gunter T; The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Ayanambakkam A; The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Wen Y; The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Cookson M; The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Stratton K; The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Source: BMJ open [BMJ Open] 2026 Apr 24; Vol. 16 (4), pp. e112623. Date of Electronic Publication: 2026 Apr 24.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2044-6055
DOI:10.1136/bmjopen-2025-112623